Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert J Allen

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Biological Psychiatry|September 26, 2006
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHDJohn Polzer, Mark E Bangs, Shuyu Zhang, et al.
Journal of Clinical Psychopharmacology|January 8, 2004
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessmentJoachim F Wernicke, Lenard Adler, Thomas Spencer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 24, 2009
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)Nicolas Ramoz, Claudette Boni, Anncatherine M Downing, et al.
Journal of Child and Adolescent Psychopharmacology|September 8, 2007
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorderSusan S F Gau, Yu-Shu Huang, Wei-Tsuen Soong, et al.
Pediatric Research|January 28, 2023
Establishing a global regulatory floor for children's decisions about participation in clinical researchSteven Joffe, Albert J Allen, Jonathan M Davis, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetineLenard A Adler, Virginia K Sutton, Rodney J Moore, et al.
Pediatrics|July 3, 2004
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trialDouglas K Kelsey, Calvin R Sumner, Charles D Casat, et al.
The American Journal of Psychiatry|November 2, 2002
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled studyDavid Michelson, Albert J Allen, Joan Busner, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2007
High-dose atomoxetine treatment of ADHD in youths with limited response to standard dosesChristopher J Kratochvil, David Michelson, Jeffrey H Newcorn, et al.
Journal of Child and Adolescent Psychopharmacology|September 8, 2007
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression, Mark E Bangs, Graham J Emslie, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Biological Psychiatry|September 26, 2006
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHDJohn Polzer, Mark E Bangs, Shuyu Zhang, et al.
Journal of Clinical Psychopharmacology|January 8, 2004
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessmentJoachim F Wernicke, Lenard Adler, Thomas Spencer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 24, 2009
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)Nicolas Ramoz, Claudette Boni, Anncatherine M Downing, et al.
Journal of Child and Adolescent Psychopharmacology|September 8, 2007
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorderSusan S F Gau, Yu-Shu Huang, Wei-Tsuen Soong, et al.
Pediatric Research|January 28, 2023
Establishing a global regulatory floor for children's decisions about participation in clinical researchSteven Joffe, Albert J Allen, Jonathan M Davis, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetineLenard A Adler, Virginia K Sutton, Rodney J Moore, et al.
Pediatrics|July 3, 2004
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trialDouglas K Kelsey, Calvin R Sumner, Charles D Casat, et al.
The American Journal of Psychiatry|November 2, 2002
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled studyDavid Michelson, Albert J Allen, Joan Busner, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2007
High-dose atomoxetine treatment of ADHD in youths with limited response to standard dosesChristopher J Kratochvil, David Michelson, Jeffrey H Newcorn, et al.
Journal of Child and Adolescent Psychopharmacology|September 8, 2007
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression, Mark E Bangs, Graham J Emslie, et al.
Pageof 6